- Scancell Holdings, The Addario Lung Cancer Medical Institute (ALCMI) and the Bonnie J. Addario Lung Cancer Foundation (ALCF) announce a collaboration to evaluate the use of the company's second innovative cancer vaccine, SCIB2, from its ImmunoBody platform to treat non-small cell lung cancer (NSCLC).

Scancell's ImmunoBody cancer vaccine platform was a novel immunotherapy treatment under development that stimulated the immune system to potentially treat and prevent cancer.

The Company recently successfully completed a Phase 1/2 clinical trial with SCIB1 in patients with melanoma.

The Addario Advanced Collaboration Program brought patients into clinical trials from ALCMI's extensive research consortium of international researchers and member institutions and ALCF's patient support programmes.

ALCMI planned to assist Scancell in the design and development of a Phase 1/2 clinical trial with SCIB2 in patients with NSCLC which was planned to begin in 2018 and complete about 18 months later.

"This partnership enables us to access an important clinical programme that could also accelerate the development of this groundbreaking immunotherapy technology," said ALCMI President and COO Steven Young.

"Combining our two foundations' unique resources will increase patient engagement with the goal to bring new treatment options to non-small cell lung cancer patients," added Bonnie J. Addario, a 12-year lung cancer survivor and founder and chair of ALCF and founder of ALCMI.

Story provided by